161 related articles for article (PubMed ID: 32576853)
1. Genome-wide DNA methylation analysis of KRAS mutant cell lines.
Tew BY; Durand JK; Bryant KL; Hayes TK; Peng S; Tran NL; Gooden GC; Buckley DN; Der CJ; Baldwin AS; Salhia B
Sci Rep; 2020 Jun; 10(1):10149. PubMed ID: 32576853
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis.
Bjaanæs MM; Fleischer T; Halvorsen AR; Daunay A; Busato F; Solberg S; Jørgensen L; Kure E; Edvardsen H; Børresen-Dale AL; Brustugun OT; Tost J; Kristensen V; Helland Å
Mol Oncol; 2016 Feb; 10(2):330-43. PubMed ID: 26601720
[TBL] [Abstract][Full Text] [Related]
3. Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors.
Kazi A; Xiang S; Yang H; Chen L; Kennedy P; Ayaz M; Fletcher S; Cummings C; Lawrence HR; Beato F; Kang Y; Kim MP; Delitto A; Underwood PW; Fleming JB; Trevino JG; Hamilton AD; Sebti SM
Clin Cancer Res; 2019 Oct; 25(19):5984-5996. PubMed ID: 31227505
[TBL] [Abstract][Full Text] [Related]
4. Mutant KRAS Downregulates the Receptor for Leukemia Inhibitory Factor (LIF) to Enhance a Signature of Glycolysis in Pancreatic Cancer and Lung Cancer.
Liu S; Gandler HI; Tošić I; Ye DQ; Giaccone ZT; Frank DA
Mol Cancer Res; 2021 Aug; 19(8):1283-1295. PubMed ID: 33931487
[TBL] [Abstract][Full Text] [Related]
5. Aurora A kinase and its activator TPX2 are potential therapeutic targets in KRAS-induced pancreatic cancer.
Gomes-Filho SM; Dos Santos EO; Bertoldi ERM; Scalabrini LC; Heidrich V; Dazzani B; Levantini E; Reis EM; Bassères DS
Cell Oncol (Dordr); 2020 Jun; 43(3):445-460. PubMed ID: 32193808
[TBL] [Abstract][Full Text] [Related]
6. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
Wang H; Lv Q; Xu Y; Cai Z; Zheng J; Cheng X; Dai Y; Jänne PA; Ambrogio C; Köhler J
EBioMedicine; 2019 Nov; 49():106-117. PubMed ID: 31668570
[TBL] [Abstract][Full Text] [Related]
7. Syndecan-1 and KRAS Gene Expression Signature Associates With Patient Survival in Pancreatic Cancer.
Wu Y; Huang H; Fervers B; Lu L
Pancreas; 2020 Oct; 49(9):1187-1194. PubMed ID: 32898003
[TBL] [Abstract][Full Text] [Related]
8. ARID1A facilitates KRAS signaling-regulated enhancer activity in an AP1-dependent manner in colorectal cancer cells.
Sen M; Wang X; Hamdan FH; Rapp J; Eggert J; Kosinsky RL; Wegwitz F; Kutschat AP; Younesi FS; Gaedcke J; Grade M; Hessmann E; Papantonis A; Strӧbel P; Johnsen SA
Clin Epigenetics; 2019 Jun; 11(1):92. PubMed ID: 31217031
[TBL] [Abstract][Full Text] [Related]
9. Aberrant epigenetic inactivation of RASSF1A and MGMT gene and genetic mutations of KRAS, cKIT and BRAF in Indian testicular germ cell tumours.
Ahmad F; Surve P; Natarajan S; Patil A; Pol S; Patole K; Das BR
Cancer Genet; 2020 Feb; 241():42-50. PubMed ID: 31653608
[TBL] [Abstract][Full Text] [Related]
10. A CRISPR-Cas13a system for efficient and specific therapeutic targeting of mutant KRAS for pancreatic cancer treatment.
Zhao X; Liu L; Lang J; Cheng K; Wang Y; Li X; Shi J; Wang Y; Nie G
Cancer Lett; 2018 Sep; 431():171-181. PubMed ID: 29870774
[TBL] [Abstract][Full Text] [Related]
11. Pivotal Role of the Chromatin Protein Nupr1 in Kras-Induced Senescence and Transformation.
Grasso D; Bintz J; Lomberk G; Molejon MI; Loncle C; Garcia MN; Lopez MB; Urrutia R; Iovanna JL
Sci Rep; 2015 Nov; 5():17549. PubMed ID: 26617245
[TBL] [Abstract][Full Text] [Related]
12. MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survival.
Lee CS; Lee LC; Yuan TL; Chakka S; Fellmann C; Lowe SW; Caplen NJ; McCormick F; Luo J
Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4508-4517. PubMed ID: 30709910
[TBL] [Abstract][Full Text] [Related]
13. A novel sensitive detection method for DNA methylation in circulating free DNA of pancreatic cancer.
Shinjo K; Hara K; Nagae G; Umeda T; Katsushima K; Suzuki M; Murofushi Y; Umezu Y; Takeuchi I; Takahashi S; Okuno Y; Matsuo K; Ito H; Tajima S; Aburatani H; Yamao K; Kondo Y
PLoS One; 2020; 15(6):e0233782. PubMed ID: 32520974
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
15. An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer.
Vallejo A; Perurena N; Guruceaga E; Mazur PK; Martinez-Canarias S; Zandueta C; Valencia K; Arricibita A; Gwinn D; Sayles LC; Chuang CH; Guembe L; Bailey P; Chang DK; Biankin A; Ponz-Sarvise M; Andersen JB; Khatri P; Bozec A; Sweet-Cordero EA; Sage J; Lecanda F; Vicent S
Nat Commun; 2017 Feb; 8():14294. PubMed ID: 28220783
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling.
Nones K; Waddell N; Song S; Patch AM; Miller D; Johns A; Wu J; Kassahn KS; Wood D; Bailey P; Fink L; Manning S; Christ AN; Nourse C; Kazakoff S; Taylor D; Leonard C; Chang DK; Jones MD; Thomas M; Watson C; Pinese M; Cowley M; Rooman I; Pajic M; ; Butturini G; Malpaga A; Corbo V; Crippa S; Falconi M; Zamboni G; Castelli P; Lawlor RT; Gill AJ; Scarpa A; Pearson JV; Biankin AV; Grimmond SM
Int J Cancer; 2014 Sep; 135(5):1110-8. PubMed ID: 24500968
[TBL] [Abstract][Full Text] [Related]
17. Expression profiling of the influence of RAS mutants on the TGFB1-induced phenotype of the pancreatic cancer cell line PANC-1.
Fensterer H; Giehl K; Buchholz M; Ellenrieder V; Buck A; Kestler HA; Adler G; Gierschik P; Gress TM
Genes Chromosomes Cancer; 2004 Mar; 39(3):224-35. PubMed ID: 14732924
[TBL] [Abstract][Full Text] [Related]
18. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
19. KRAS promotes tumor metastasis and chemoresistance by repressing RKIP via the MAPK-ERK pathway in pancreatic cancer.
Yang K; Li Y; Lian G; Lin H; Shang C; Zeng L; Chen S; Li J; Huang C; Huang K; Chen Y
Int J Cancer; 2018 Jun; 142(11):2323-2334. PubMed ID: 29315556
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic KRAS Induces NIX-Mediated Mitophagy to Promote Pancreatic Cancer.
Humpton TJ; Alagesan B; DeNicola GM; Lu D; Yordanov GN; Leonhardt CS; Yao MA; Alagesan P; Zaatari MN; Park Y; Skepper JN; Macleod KF; Perez-Mancera PA; Murphy MP; Evan GI; Vousden KH; Tuveson DA
Cancer Discov; 2019 Sep; 9(9):1268-1287. PubMed ID: 31263025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
